Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Brain Behav Immun. 2014 Dec 16;45:98–108. doi: 10.1016/j.bbi.2014.12.015

Figure 1. CXCR4+CD45− BMMNCs reduce infarct volume and neurologic deficits in mice after tMCAO.

Figure 1

(A) A representative panel of brain slices stained by TTC on day 7 after tMCAO illustrates the infarction volume in mice treated with different cell populations; areas of infarct are white. (B) Corrected infarction volume was calculated as a percentage of the contralateral area. The infarction volume of the CXCR4+CD45− BMMNC-treated group was significantly less than that of the unfractionated BMMNC-treated group. n=6 mice/group; **p<0.01 vs. vehicle; ##p<0.01 vs. unfractionated BMMNCs; one-way ANOVA followed by LSD analysis. (C) Modified neurologic severity scores of mice at 1, 7, and 14 days after tMCAO. n=12 mice/group; **p<0.01 vs. vehicle; ##p<0.01, ###p<0.001 vs. unfractionated BMMNCs by one-way ANOVA followed by LSD analysis.